EDIT - Editas Medicine: Primed For An Unlikely Comeback? It's Not Impossible
2025-07-30 16:57:48 ET
Investment Overview
Editas ( EDIT ) is a company I have not covered for Seeking Alpha in some time - since December 2022 in fact - largely because its share price has been in near constant decline, ever since hitting highs of >$90 per share in early 2021 based on the promise of CRISPR/Cas9 gene editing technology....
Editas Medicine: Primed For An Unlikely Comeback? It's Not Impossible